Abstracts tagged "SYK and rheumatoid arthritis (RA)"

Abstract Number: 2518 • 2018 ACR/ARHP Annual Meeting
GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study
Alan J. Kivitz¹, Daksha P Mehta², Franziska Matzkies³, Afsaneh Mozaffarian³, Rebecca Kunder³, Julie Di Paolo⁴, Neelufar Mozaffarian³, Sean Hsueh³, JiYun Kim⁵, Wendy Jiang³, Lin Liu³, John S. Sundy⁶ and Mark C. Genovese⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Center for Arthritis and Osteoporosis, Elizabethtown, KY, ³Gilead Sciences, Inc., Foster City, CA, ⁴Immunology and Inflammation Biology, Gilead Sciences, Inc., Foster City, CA, ⁵Biomarkers, Gilead Sciences, Inc., Foster City, CA, ⁶Clinical Research, Inflammation and Respiratory, Gilead Sciences, Inc., Foster City, CA, ⁷Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Spleen tyrosine kinase (SYK) mediates immunoreceptor signaling and is essential in activation of cells including B lymphocytes, monocytes, macrophages, dendritic cells, and osteoclasts. SYK…
Abstract Number: 1621 • 2016 ACR/ARHP Annual Meeting
A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Hmpl‑523 in Australian Male Healthy Subjects
Jason Lickliter¹, Yan Wu², Ye Hua², Irena Yuan², Guangxiu Dai², Xiong Li², Jian Wang², Yang Sai², Zhongcui Sun², Angela Pan², Jing Li² and Weiguo Su², ¹Nucleus Network, Melbourne, Australia, ²Hutchison MediPharma Limited, Shanghai, China
Background/Purpose: Spleen Tyrosine Kinase (SYK) plays a pivotal role in the regulation of downstream signals in immune receptors, including B cell receptors (BCRs), which…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].